Kastrationsresistentes Prostatakarzinom: Enzalutamid besser als Placebo
- PMID: 30731496
- DOI: 10.1055/a-0830-9049
Kastrationsresistentes Prostatakarzinom: Enzalutamid besser als Placebo
Conflict of interest statement
Disclosure The authors report no conflicts of interest in this work.
Comment on
-
Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer.N Engl J Med. 2018 Jun 28;378(26):2465-2474. doi: 10.1056/NEJMoa1800536. N Engl J Med. 2018. PMID: 29949494 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources